Mini Review
Volume 09:01, 2024

Journal of Inflammatory Bowel Diseases & Disorders

ISSN: 2476-1958 Open Access

An International Method for Monitoring Celiac Disease

Gessella Pillar*

Department of Special Surgery, Children's National Hospital 111 Michigan Avenue NW, Washington, DC 20010, USA

Abstract

Celiac Disease (CD) is a chronic autoimmune disorder primarily affecting the small intestine, triggered by the ingestion of gluten in genetically predisposed individuals. It is characterized by a wide range of clinical manifestations, from gastrointestinal symptoms to extra-intestinal symptoms such as anemia, osteoporosis, and neurological issues. The only effective treatment for CD is a strict, lifelong Gluten-free diet. However, monitoring adherence to this diet and assessing disease activity present significant challenges. An international method for monitoring celiac disease involves standardized approaches to diagnosis, follow-up, and management, incorporating serological, histological, and clinical evaluations.

The diagnosis of CD typically involves a combination of serological tests, genetic testing, and intestinal biopsy. The most common serological markers include anti-tissue Trans Glutaminase (tTG) antibodies and anti-endo mysial antibodies. The presence of these antibodies suggests an autoimmune response to gluten. Genetic testing can identify the presence of HLA-DQ2 or HLA-DQ8 haplotypes, which are necessary but not sufficient for the development of CD. A definitive diagnosis often requires a biopsy of the small intestine to confirm villous atrophy and crypt hyperplasia.

Keywords: Celiac disease • Trans glutaminase • Gluten-free diet

Introduction

Anti-tissue Transglutaminase (tTG) Antibodies: tTG-IgA is the primary test due to its high sensitivity and specificity. In IgA-deficient patients, tTG-IgG can be used. Anti-endomysial Antibodies (EMA): EMA-IgA testing is highly specific but less commonly used due to its higher cost and the requirement for indirect immunofluorescence. Deamidated Gliadin Peptide (DGP) Antibodies: DGP-IgA and DGP-IgG tests can be useful, especially in young children or in those with IgA deficiency. Genetic testing for HLA-DQ2 and HLA-DQ8 can help exclude CD in individuals with low pre-test probability, as the absence of these haplotypes makes CD very unlikely.

Once diagnosed, monitoring CD involves assessing adherence to the GFD, evaluating symptom resolution, and detecting potential complications. This requires a combination of clinical follow-up, serological testing, dietary review, and sometimes repeat biopsy. Regular follow-up with a healthcare provider is essential to assess symptom resolution and manage any ongoing issues. Patients should be regularly questioned about gastrointestinal symptoms (e.g., diarrhea, bloating, abdominal pain) and extra-intestinal symptoms (e.g., fatigue, anemia).

Literature Review

Monitoring for signs of malnutrition or complications such as osteoporosis. Serological tests are crucial in monitoring adherence to a GFD. A decline in tTG and EMA levels usually indicates compliance with the diet and mucosal healing. Persistent elevation of these antibodies suggests ongoing gluten exposure. These should be checked 6-12 months after diagnosis and periodically thereafter.May be used in specific cases where tTG or EMA levels are inconclusive. A detailed dietary review by a dietitian experienced in CD is vital.

Assessing for potential sources of gluten contamination.Ensuring adequate intake of essential nutrients, especially those often deficient in CD patients, such as iron, calcium, and vitamin D. In some cases, particularly if symptoms persist despite a strict GFD or if there is suspicion of complications like refractory CD, a repeat biopsy may be warranted to assess mucosal healing. A rare condition where symptoms and intestinal damage persist despite strict adherence to a GFD. CD patients have an increased risk of certain cancers, such as enteropathy-associated T-cell lymphoma (EATL) and small bowel adenocarcinoma.Due to malabsorption of calcium and vitamin D. CD is associated with other autoimmune conditions, including type 1 diabetes and autoimmune thyroid disease. Regular screening and appropriate management of these conditions are crucial in CD patients. Internationally, there is a need for standardized protocols for the monitoring of CD to ensure consistent and effective management. These protocols should be evidence-based and include guidelines.

Discussion

Regular visits with healthcare providers, typically every 6-12 months. Periodic testing of tTG and EMA levels. Regular reviews by a dietitian. Guidelines for monitoring bone density, screening for associated autoimmune conditions, and surveillance for malignancies.Several organizations have developed guidelines for the management of CD, Provides comprehensive guidelines for diagnosis and management, including follow-up protocols. World Gastroenterology Organisation (WGO): Provides global guidelines that consider resource variations in different countries.

Patient education and support are crucial components of successful CD management. Patients need to be well-informed about their condition and the importance of adhering to a GFD. Support groups and resources can help patients navigate the challenges of living with CD. These should cover the basics of CD, the gluten-free diet, and potential sources of gluten contamination. Local and online support groups provide community and resources for patients. There are various apps available that help patients identify gluten-free foods and manage their diet.Ongoing research is essential to improve the monitoring and management of CD. Development of tools such as stool tests or urine tests to detect gluten ingestion [1-6].

***Address for Correspondence:** Gessella Pillar, Department of Special Surgery, Children's National Hospital 111 Michigan Avenue NW, Washington, DC 20010, USA; E-mail: gessella@pillar.edu*

Received: 29 January, 2024, Manuscript No. jbabm-24-135336; **Editor Assigned:** 31 January, 2024, PreQC No. P-135336; **Reviewed:** 14 February, 2024, QC No. Q-135336; **Revised:** 20 February, 2024, Manuscript No. R-135336; **Published:** 28 February 2024, DOI: 10.37421/2476-1958.2024.9.196

Conclusion

Identifying new biomarkers that can provide more accurate monitoring of disease activity.Research into potential therapies that could supplement or replace the GFD, such as enzyme therapies or vaccines.Monitoring celiac disease effectively requires a comprehensive and standardized approach that includes regular clinical follow-up, serological testing, dietary assessments, and monitoring for complications. International guidelines help standardize care, ensuring that patients receive consistent and effective management. Patient education and support are also vital components of successful CD management. Advances in research hold promise for improved monitoring and treatment options in the future. Through a collaborative and patient-centered approach, the global celiac community can work towards better health outcomes for all individuals affected by this challenging condition.

Acknowledgement

None.

Conflict of Interest

None.

References

1. González, Teba, Idoia Larretxi, Juan Carlos Vitoria and Luis Castaño, et al. "Celiac male's gluten-free diet profile: Comparison to that of the control population and celiac women." *Nutr* 10 (2018): 1713.
2. Miranda, J., A. Lasa, M. A. Bustamante and I. Churruca, et al. "Nutritional differences between a gluten-free diet and a diet containing equivalent products with gluten." *Plant Foods Hum Nutr* 69 (2014): 182-187.
3. Sevinç, Eylem, Fatih Hilmi Çetin and Banu Demet Coşkun. "Psychopathology, quality of life, and related factors in children with celiac disease." *J Pediatr* 93 (2017): 267-273.
4. Cataldo, Francesco and Giuseppe Montalto. "Celiac disease in the developing countries: A new and challenging public health problem." World J Gastroenterol 13 (2007): 2153.
5. Ben Houmich, Taoufik, and Brahim Admou. "Celiac disease: Understandings in diagnostic, nutritional, and medicinal aspects." *Int J Immunopathol Pharmacol* 35 (2021): 20587384211008709.
6. Matoori, Simon, Gregor Fuhrmann and Jean-Christophe Leroux. "Celiac disease: A challenging disease for pharmaceutical scientists." *Pharm Res* 30 (2013): 619-626.

How to cite this article: Pillar, Gessella. "An International Method for Monitoring Celiac Disease." J Inflamm Bowel Dis 9 (2024): 196.